Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

710
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
710

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunohistochemistry-guided analyses of steroidogenesis in primary bilateral macronodular adrenal hyperplasia.

The Journal of endocrinology·2025
Same author

Altered Microbiome Signature in Cushing's Syndrome Persists Beyond Remission.

The Journal of clinical endocrinology and metabolism·2024
Same author

Polymorphism in the Drug Transporter Gene ABCB1 as a Potential Disease Modifier in Cortisol-Producing Adrenal Adenomas.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2024
Same author

Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial.

JAMA·2024
Same author

Unilateral Primary Aldosteronism: Long-Term Disease Recurrence After Adrenalectomy.

Hypertension (Dallas, Tex. : 1979)·2024
Same journal

Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.

Journal of hypertension·2026
Same journal

Erratum: Feasibility of the extended, 48-h ambulatory blood pressure monitoring in hemodialysis patients: a multicenter study.

Journal of hypertension·2026
Same journal

Erratum: Neurofibromatosis 2 alleviates ferroptosis and fibrosis in the aortas of spontaneously hypertensive rats through the Yes-associated protein pathway.

Journal of hypertension·2026
Same journal

Reply to comment: Limited public understanding of the risk factors and complications of hypertension.

Journal of hypertension·2026
Same journal

What magnesium depletion score can tell us about arterial stiffness.

Journal of hypertension·2026
Same journal

Nephron deficit as susceptibility, not determinism.

Journal of hypertension·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.5K

The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for

Hanna Remde1, Anna Dietz, Rebecca Emeny

  • 1aClinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Berlin bMedizinische Klinik und Poliklinik IV, University Hospital Munich, Munich cHelmholtz Zentrum München, Institute of Epidemiology II, German Research Center for Environmental Health, Neuherberg dGerman Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich eEndocrinology in Charlottenburg, Berlin, Germany.

Journal of Hypertension
|July 22, 2016
PubMed
Summary
This summary is machine-generated.

Copeptin and high-sensitive C-reactive protein (hsCRP) levels decrease after primary aldosteronism treatment, indicating reduced cardiovascular risk. However, these biomarkers do not independently predict treatment cure.

More Related Videos

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.5K
Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney
10:00

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney

Published on: October 12, 2015

12.3K

Related Experiment Videos

Last Updated: Mar 17, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

24.5K
Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay
07:14

Detection and Quantification of Calcitonin Gene-Related Peptide CGRP in Human Plasma Using a Modified Enzyme-Linked Immunosorbent Assay

Published on: June 16, 2023

3.5K
Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney
10:00

Use of Enzymatic Biosensors to Quantify Endogenous ATP or H2O2 in the Kidney

Published on: October 12, 2015

12.3K

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Biomarker Research

Background:

  • Copeptin and high-sensitive C-reactive protein (hsCRP) are established mortality risk markers in cardiovascular and general populations.
  • No prior data existed on these biomarkers in patients with primary aldosteronism.

Purpose of the Study:

  • To investigate copeptin and hsCRP as potential cardiovascular risk markers in primary aldosteronism.
  • To assess changes in these biomarkers following treatment for primary aldosteronism.

Main Methods:

  • A cohort of 113 primary aldosteronism patients was matched with 339 controls from a population-based survey.
  • Copeptin and hsCRP levels were measured at baseline and after treatment initiation.
  • Statistical analysis compared biomarker levels between patients and controls, and assessed changes post-treatment.

Main Results:

  • Primary aldosteronism patients exhibited higher baseline hsCRP compared to controls.
  • Specific therapy led to significant reductions in both hsCRP and copeptin levels.
  • While sex, hypokalemia, lateralization index, and blood pressure predicted outcomes, copeptin and hsCRP did not independently predict cure.

Conclusions:

  • Decreasing copeptin and hsCRP levels post-treatment suggest successful cardiovascular risk reduction in primary aldosteronism.
  • These biomarkers are not independent predictors of achieving a cure for primary aldosteronism.